Home

Insights

PE

Lyka Labs Ltd P/E Ratio

Lyka Labs Ltd P/E Ratio

download
stocks purchased

₹ 0.0 Cr

Volume transacted

stocks purchased

4.3 K

stocks traded

Last Updated time: 16 Jul 9.00 AM

Image

Lyka Labs Ltd

NSE: LYKALABS

PE

0

Last updated : 16 Jul 9.00 AM

Key Highlights

    The P/E Ratio of Lyka Labs Ltd is 0 as of 16 Jul 9.00 AM .a1#The P/E Ratio of Lyka Labs Ltd changed from 10 on March 2019 to 0 on March 2023 . This represents a CAGR of -100.00% over 2 years. a1#The Latest Trading Price of Lyka Labs Ltd is ₹ 111.85 as of 16 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.5 to 27.2 in 5 years. This represents a CAGR of -0.93%a1# The PE Ratio of Automobile industry is 17.2. The PE Ratio of Finance industry is 24.5. The PE Ratio of IT - Software industry is 29.2. The PE Ratio of Pharmaceuticals industry is 35.8. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 12.1. In 2024a1#The Market Cap of Lyka Labs Ltd changed from ₹ 68.94 crore on March 2019 to ₹ 300.38 crore on March 2023 . This represents a CAGR of 34.23% over 5 years. a1#The Revenue of Lyka Labs Ltd changed from ₹ 28.44 crore to ₹ 28.08 crore over 8 quarters. This represents a CAGR of -0.63% a1#The EBITDA of Lyka Labs Ltd changed from ₹ 7.25 crore to ₹ 2.34 crore over 8 quarters. This represents a CAGR of -43.19% a1#The Net Pr of Lyka Labs Ltd changed from ₹ 0.6 crore to ₹ -2.13 crore over 8 quarters. This represents a CAGR of NaN% a1#The Dividend Payout of Lyka Labs Ltd changed from 0 % on March 2019 to 0 % on March 2023 . This represents a CAGR of 0.0% over 5 years. a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

×

Historical P/E Ratio of Lyka Labs Ltd

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Historical P/E Ratio of Lyka Labs Ltd

Period
Mar '190
Mar '200
Mar '210
Mar '2210
Mar '230

Company Fundamentals for Lyka Labs Ltd

Market Cap

399 Cr

EPS

0.0

P/E Ratio (TTM) *

0.0

P/B Ratio (TTM) *

5.6

Day’s High

114.05

Day’s Low

110.0

DTE *

0.9

ROE *

-4.5

52 Week High

143.5

52 Week Low

99.95

ROCE *

3.4

* All values are consolidated

Last Updated time: 16 Jul 9.00 AM

* All values are consolidated

Last Updated time: 16 Jul 9.00 AM

Image

Lyka Labs Ltd

NSE: LYKALABS

PRICE

111.85

-0.50 (-0.45%)

stock direction

Last updated : 16 Jul 15:30

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Lyka Labs Ltd

Strength

1

S

Weakness

4

W

Opportunity

1

O

Threats

1

T

Asset Value vs Market Value of Lyka Labs Ltd

Market Value

399

Asset Value

44

8.0 X

Value addition

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Lyka Labs Ltd0399
Sun Pharmaceuticals Industries Ltd37378,915
Cipla Ltd28122,044
Divis Laboratories Ltd75121,185
Zydus Lifesciences Ltd30119,224
Dr Reddys Laboratories Ltd20110,827

Key Valuation Metric of Lyka Labs Ltd

Earnings

-2 Cr

0.0 X

PE Ratio

Market Cap

₹399.19Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Earnings

-2 Cr

0.0 X

PE Ratio

Market Cap

₹399.19Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

×

Historical Market Cap of Lyka Labs Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of Lyka Labs Ltd

Period
Mar '1969
Mar '2037
Mar '2175
Mar '22389
Mar '23300

* All values are a in crore

×

Historical Revenue of Lyka Labs Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of Lyka Labs Ltd

Period
Jun '2228
Sep '2227
Dec '2219
Mar '2323
Jun '2323
Sep '2328
Dec '2333
Mar '2428

* All values are a in crore

×

Historical EBITDA of Lyka Labs Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of Lyka Labs Ltd

Period
Jun '227
Sep '226
Dec '22-4
Mar '233
Jun '233
Sep '234
Dec '237
Mar '242

* All values are a in crore

×

Historical Net Profit of Lyka Labs Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of Lyka Labs Ltd

Period
Jun '221
Sep '220
Dec '22-10
Mar '23-3
Jun '23-2
Sep '230
Dec '232
Mar '24-2

* All values are a in crore

×

Historical Dividend Payout of Lyka Labs Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of Lyka Labs Ltd

Period
Mar '190
Mar '200
Mar '210
Mar '220
Mar '230

* All values are a in %

About Lyka Labs Ltd

About Lyka Labs Ltd

    Initially manufacturing formulations, Lyka Labs brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. '83. It also added a range of ayurvedic and animal health care products over the years. In 1990, it diversified into marketing medical and diagnostic equipment and instruments of Bekton Dickinson, US; Airsep Corporation, US; Coloplast, Denmark; and Terumo Corporation, Japan. Lyka Exports is the subsidiary of the company. The company offers a broad range of antibiotics used as life-savers and to treat minor infections. It has a fairly widespread product base with tropical steroids for skin disorders, anti-cancer products, cardio-vascular drugs and anti-inflammatory products. Lyka introduced, in India, cough lozenges containing dextromethorphan hydrobromide (DMR), favoured internationally as an effective and safe cough suppressant. Lyka has two formulations division and a bulk drugs division. It also set up additional manufacturing facilities for ointments. As part of its diversification, it has invested in Relic Finance, a company carrying on the business of finance and merchant banking. A GOI-recognised Export House, it received the Certificate of Merit for its excellent export performance in 1993-94. In the same year, it received an award from CHEMEXCIL for its outstanding performance. During 1997-98, the company's administrative office & plant at tarapur has been awarded ISO 9002 certification for its quality management system by SGS Yarsley International Certification Services Limited, UK. The production carried out at Bombay has been shifted to Tarapur and Ankleshwar in the year 1999-2000, inorder to achieve economies of scale and better compliance. The company has assigned Trade Marks and transferred technical, marketing know-how and allied rights pertaining to some of its products. The Company's factory at Tarapur, re-commissioned production in March, 2013. It launched Glutathione Injection, a 'First Time in India' formulation during 2012-13. It commissioned the production at Ankleshwar factory. During Financial Year 2013-14, the Company had floated a Wholly Owned Subsidiary Company namely Lyka Healthcare Limited to focus, develop and expand Domestic Marketing of Ethical Products. Its another subsidiary, Lyka Exports Limited reorganized its activities and resultant, it sold the Animal Healthcare Business in 2014. The subsidiaries, Lyka Healthcare Limited and Lyka Exports Limited merged with the Company which became effective from April 01, 2016. During the year 2021-22, IPCA together with persons acting in concert acquired 26.70% shares of the Company through Public Offer consisting a total shareholding of 27.76% of the Paid-up Equity Capital of the Company and resultant to acquisition in stake, became the Joint Promoters of Company.

Lyka Labs Ltd News Hub

News

Lyka Labs to convene AGM

Lyka Labs announced that the Annual General Meeting (AGM) of the company will be held on 9...

Read more

16 Jul 202410:33

News

Lyka Labs to hold board meeting

Lyka Labs will hold a meeting of the Board of Directors of the Company on 21 May 2024 Powe...

Read more

10 May 202416:12

News

Lyka Labs to convene board meeting

Lyka Labs will hold a meeting of the Board of Directors of the Company on 16 April 2024. P...

Read more

09 Apr 202409:31

News

Lyka Labs to declare Quarterly Result

Lyka Labs will hold a meeting of the Board of Directors of the Company on 8 February 2024....

Read more

01 Feb 202417:40

News

Lyka Labs to conduct EGM

Lyka Labs announced that an Extra Ordinary General Meeting (EGM) of the Company will be he...

Read more

19 Jan 202415:35

News

Lyka Labs to hold board meeting

Lyka Labs will hold a meeting of the Board of Directors of the Company on 2 November 2023....

Read more

21 Oct 202312:11

Product Composition by Percentage (Revenue)

FAQs for PE of Lyka Labs Ltd

What is Lyka Labs Ltd current share price?

The current market price of Lyka Labs Ltd as of July 16, 2024 is ₹111.85.

What is Lyka Labs Ltd's market cap?

Lyka Labs Ltd's market capitalisation stood at ₹399 Cr as of July 16, 2024

What are Lyka Labs Ltd's total net assets?

According to Lyka Labs Ltd's most recent financial filings, the company's net assets total ₹44.2 Cr.

Is Lyka Labs Ltd making a profit or loss?

Lyka Labs Ltd's net Profit as of July 16, 2024 is close to ₹-2 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199